KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion clinical trials

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma

This study looks at a new treatment called IMCgp100 for advanced eye melanoma that has not been treated before. It compares this new drug to standard treatments to see which works best and is safest for patients.